The MEA diabetic retinopathy market is projected to grow from USD 810 million in 2025 to approximately USD 1.59 billion by 2035, at a CAGR of 7%. Growth is driven by the rising prevalence of diabetes, increasing awareness of eye health, and advancements in retinal diagnostic and treatment technologies.

MEA Diabetic Retinopathy Market Statical Scope

Research studies implied that the high prevalence of diabetes in the world is in six of the 10 countries in the Middle East, including Lebanon, Oman, Kuwait, Bahrain, Saudi Arabia, and the United Arab Emirates. The dietary changes, sedentary lifestyles, and rapid urbanization are leading to the rising rates of diabetes. The Middle East region is also facing major health issues related to obesity, hypertension, and hyperlipidemia that further lead to retinal damage.

MEA Diabetic Retinopathy Market Share, By Type, 2025 (%)

• Non-proliferative Diabetic Retinopathy (NPDR)- The non-proliferative diabetic retinopathy segment accounts for a revenue share of 65%, owing to the primary goal of this treatment to reach systemic control, monitoring, and intervention.
• Proliferative Diabetic Retinopathy (PDR)- The proliferative diabetic retinopathy segment leads to a share of 35%, due to the increased concerns of sudden and severe vision loss and permanent blindness caused by proliferative diabetic retinopathy.

MEA Diabetic Retinopathy Market Share, By Management, 2025 (%)

• Anti-VEGF- The anti-VEGF segment occupies a share of 42%, driven by the importance of anti-VEGF as an established first-line treatment for diabetic macular edema in cases of vision impairment.
• Laser Surgery- The laser surgery segment holds a share of 24%, supported by the growing trend of micropulse laser therapy as a gentle and new method to deliver short pulses and reduce damage to surrounding retinal tissue.
• Intraocular Steroid Injection- The intraocular steroid injection segment drives the market with a share of 18%, accelerated by the preference for this highly effective second-line treatment for managing diabetic macular edema, reducing retinal swelling and inflammation.

Top Companies in the MEA Diabetic Retinopathy Market

• Bayer AG
• AbbVie Inc.
• Novartis AG
• Oxurion NV.
• Sirnaomics
• Alimera Sciences
• Ampio Pharmaceuticals Inc.
• BCNPeptides
• Kowa Company, Ltd.
• Genentech, Inc.

Segments Covered in the Report

By Type

• Proliferative Diabetic Retinopathy
• Non-proliferative Diabetic Retinopathy

By Management

• Anti-VEGF
• Intraocular Steroid Injection
• Laser Surgery
• Vitrectomy